MaxCyte Investor Presentation Deck

EXPERT™ Platform Addresses Industry Challenges Challenges A⁰ Lack of industry standard for process design causes development to be costly and inconsistent across manufacturing runs Next-generation cell therapy programs have become increasingly complex requiring multiple edits Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster MaxCyte's Solutions A (✓: M MaxCyte MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes and the ability to seamlessly scale up from pre-IND to the clinic and commercialization Flow Electroporation technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory review EXPERT™ platform provides industry leading transfection efficiency & cell viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation